As the East Coast’s longest standing forum for the tumor modeling community, we can help you elevate your platform and capabilities in this crowded market!
As translational rates of cancer drugs remain a mere 5%, drug developers are actively seeking the right partners to help them bridge the translational gap through better implementation of reproducible and predictive oncology models.
In July 2025, the 13th Tumor Models Summit Boston reunited 180+ preclinical, translational, pharmacology, discovery, pharmacodynamics, toxicity and biology experts from leading oncology biopharma, eager to revolutionize their drug development workflows. They were seeking support in:
Developing and optimizing tumor models to empower discovery studies for candidate selection through to toxicity with preclinical CROsÂ
Identifying and validating biomarkers to understand disease mechanism and predict patients’ response to treatment with biomarker assaysÂ
Leveraging AI tools and software to empower model selection, improve modeling techniques, identify underserved patient populations and predict effective treatment regimesÂ
Analyzing deeper levels of disease complexity by implementing highly sensitive imaging technologies Â
If your expertise aligns with the above, then this meeting is an unmissable opportunity to position yourself alongside the leading voices in the field, elevate your solutions and services, and become the ‘go-to’ partner for biopharma for all things tumor modeling and preclinical oncology-related.Â
Get in touch today if you're interested in learning about opportunities available for 2026 partnership.
